Progranulin: A key player in autoimmune diseases

Cytokine

Volumn 101, Issue , 2018, Pages 48-55

  Jian, Jinlong ^a   Li, Guangfei ^a,b   Hettinghouse, Aubryanna ^a   Liu, Chuanju ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Autoimmune diseases; Progranulin; TNF; TNFR

Indexed keywords

COLLAGENASE 3; CYCLOOXYGENASE 2; DEATH RECEPTOR 3; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; PROGRANULIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; GRN PROTEIN, HUMAN; PROTEIN BINDING; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR;

AUTOIMMUNE DISEASE; BINDING AFFINITY; CLINICAL EFFECTIVENESS; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG PROTEIN BINDING; HUMAN; INFLAMMATORY BOWEL DISEASE; INSULIN RESISTANCE; LIPID DIET; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS; COMPLICATION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-10; MACROPHAGES; MICE; OSTEOARTHRITIS; PROTEIN BINDING; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84995684631     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.08.007     Document Type: Review

References (86)

1. Zanocco-Marani, T., et al. Biological activities and signaling pathways of the granulin/epithelin precursor. Cancer Res. 59 (1999), 5331–5340.
2. Plowman, G.D., et al. The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth. J. Biol. Chem. 267 (1992), 13073–13078.
3. Shoyab, M., McDonald, V.L., Byles, C., Todaro, G.J., Plowman, G.D., Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins. Proc. Natl. Acad. Sci. U.S.A. 87 (1990), 7912–7916.
4. Anakwe, O.O., Gerton, G.L., Acrosome biogenesis begins during meiosis: evidence from the synthesis and distribution of an acrosomal glycoprotein, acrogranin, during guinea pig spermatogenesis. Biol. Reprod. 42 (1990), 317–328.
5. Zhu, J., et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111 (2002), 867–878.
6. He, Z., Ong, C.H., Halper, J., Bateman, A., Progranulin is a mediator of the wound response. Nat. Med. 9 (2003), 225–229, 10.1038/nm816.
7. Tang, W., et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332 (2011), 478–484, 10.1126/science.1199214.
8. Hrabal, R., Chen, Z., James, S., Bennett, H.P., Ni, F., The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat. Struct. Biol. 3 (1996), 747–752.
9. Kessenbrock, K., et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J. Clin. Investig. 118 (2008), 2438–2447, 10.1172/JCI34694.
10. Butler, G.S., Dean, R.A., Tam, E.M., Overall, C.M., Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol. Cell. Biol. 28 (2008), 4896–4914, 10.1128/MCB.01775-07.
11. Suh, H.S., Choi, N., Tarassishin, L., Lee, S.C., Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12). PLoS ONE, 7, 2012, e35115, 10.1371/journal.pone.0035115.
12. Xu, D., et al. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol. Cell. Proteomics: MCP 7 (2008), 2215–2228, 10.1074/mcp.M800095-MCP200.
13. Frampton, G., et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 61 (2012), 268–277, 10.1136/gutjnl-2011-300643.
14. Diaz-Cueto, L., Arechavaleta-Velasco, F., Diaz-Arizaga, A., Dominguez-Lopez, P., Robles-Flores, M., PKC signaling is involved in the regulation of progranulin (acrogranin/PC-cell-derived growth factor/granulin-epithelin precursor) protein expression in human ovarian cancer cell lines. Int. J. Gynecol. Cancer 22 (2012), 945–950, 10.1097/IGC.0b013e318253499c.
15. Serrero, G., Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis. Biochem. Biophys. Res. Commun. 308 (2003), 409–413.
16. Cruts, M., et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442 (2006), 920–924, 10.1038/nature05017.
17. Baker, M., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442 (2006), 916–919, 10.1038/nature05016.
18. Baker, C.A., Manuelidis, L., Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 675–679, 10.1073/pnas.0237313100.
19. Vercellino, M., et al. Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Mult. Scler. 17 (2011), 1194–1201, 10.1177/1352458511406164.
20. Malaspina, A., Kaushik, N., de Belleroche, J., Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem. 77 (2001), 132–145.
21. Lopez de Munain, A., et al. Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings. Biol. Psychiatry 63 (2008), 946–952, 10.1016/j.biopsych.2007.08.015.
22. Jian, J., et al. Progranulin directly binds to the CRD2 and CRD3 of TNFR extracellular domains. FEBS Lett. 587 (2013), 3428–3436, 10.1016/j.febslet.2013.09.024.
23. Al-Lamki, R.S., Mayadas, T.N., TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int. 87 (2015), 281–296, 10.1038/ki.2014.285.
24. Doss, G.P., Agoramoorthy, G., Chakraborty, C., TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseases. Front Biosci. (Landmark Ed) 19 (2014), 1028–1040.
25. Liu, C., Li, X.X., Gao, W., Liu, W., Liu, D.S., Progranulin-derived Atsttrin directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity. PLoS ONE, 9, 2014, e92743, 10.1371/journal.pone.0092743.
26. Aiba, Y., Nakamura, M., The role of TL1A and DR3 in autoimmune and inflammatory diseases. Mediators Inflamm., 2013, 2013, 258164, 10.1155/2013/258164.
27. Richard, A.C., et al. The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator. J. Leukoc. Biol. 98 (2015), 333–345, 10.1189/jlb.3RI0315-095R.
28. Wei, F., Zhang, Y., Zhao, W., Yu, X., Liu, C.J., Progranulin facilitates conversion and function of regulatory T cells under inflammatory conditions. PLoS ONE, 9, 2014, e112110, 10.1371/journal.pone.0112110.
29. Wei, F., et al. PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner. Sci. Reports, 4, 2014, 7023, 10.1038/srep07023.
30. Mundra, J.J., Jian, J., Bhagat, P., Liu, C.J., Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner. Sci. Reports(6), 2016, 21115, 10.1038/srep21115.
31. Aggarwal, B.B., Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3 (2003), 745–756, 10.1038/nri1184.
32. Li, P., Schwarz, E.M., The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin. Immunopathol. 25 (2003), 19–33, 10.1007/s00281-003-0125-3.
33. Thwin, M.M., et al. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res. Therapy 6 (2004), R282–294, 10.1186/ar1179.
34. Yamamoto, Y., et al. Increased serum GP88 (Progranulin) concentrations in rheumatoid arthritis. Inflammation 37 (2014), 1806–1813, 10.1007/s10753-014-9911-4.
35. Cerezo, L.A., et al. Progranulin is associated with disease activity in patients with rheumatoid arthritis. Mediators Inflamm., 2015, 2015, 740357, 10.1155/2015/740357.
36. Chen, J., et al. Serum progranulin irrelated with Breg cell levels, but elevated in RA patients, reflecting high disease activity. Rheumatol. Int. 36 (2016), 359–364, 10.1007/s00296-015-3372-4.
37. Malfait, A.M., Osteoarthritis year in review 2015: biology. Osteoarthr. Cartilage/OARS, Osteoarthr. Res. Soc. 24 (2016), 21–26, 10.1016/j.joca.2015.09.010.
38. Guo, F., et al. Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. Arthritis Rheum. 62 (2010), 2023–2036, 10.1002/art.27491.
39. Zhao, Y.P., et al. Progranulin protects against osteoarthritis through interacting with TNF-alpha and beta-Catenin signalling. Ann. Rheum. Dis. 74 (2015), 2244–2253, 10.1136/annrheumdis-2014-205779.
40. Zhao, Y., Liu, B., Liu, C.J., Establishment of a surgically-induced model in mice to investigate the protective role of progranulin in osteoarthritis. J. Visualized Exp.: JoVE, 2014, e50924, 10.3791/50924.
41. Xia, Q., et al. Intra-articular transplantation of atsttrin-transduced mesenchymal stem cells ameliorate osteoarthritis development. Stem cells Translational Med. 4 (2015), 523–531, 10.5966/sctm.2014-0200.
42. Scott, L.J., Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs 74 (2014), 1379–1410, 10.1007/s40265-014-0258-9.
43. Kimmerling, K.A., et al. Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis. Eur. Cells Mater. 29 (2015), 124–139 discussion 139-140.
44. Olson, S.A., Furman, B.D., Kraus, V.B., Huebner, J.L., Guilak, F., Therapeutic opportunities to prevent post-traumatic arthritis: lessons from the natural history of arthritis after articular fracture. J. Orthop. Res.: Official Publ. Orthop. Res. Soc. 33 (2015), 1266–1277, 10.1002/jor.22940.
45. Wei, J.L., Buza, J. 3rd, Liu, C.J., Does progranulin account for the opposite effects of etanercept and infliximab/adalimumab in osteoarthritis?: Comment on Olson et al.: “Therapeutic Opportunities to Prevent Post-Traumatic Arthritis: Lessons From the Natural History of Arthritis After Articular Fracture”. J. Orthop. Res.: Official Publ. Orthop. Res. Soc. 34 (2016), 12–14, 10.1002/jor.23091.
46. Abella, V., et al. The novel adipokine progranulin counteracts IL-1 and TLR4-driven inflammatory response in human and murine chondrocytes via TNFR1. Sci. Reports, 6, 2016, 20356, 10.1038/srep20356.
47. Zhao, Y.P., Tian, Q.Y., Frenkel, S., Liu, C.J., The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling. Biomaterials 34 (2013), 6412–6421, 10.1016/j.biomaterials.2013.05.030.
48. Olesen, C.M., Coskun, M., Peyrin-Biroulet, L., Nielsen, O.H., Mechanisms behind efficacy of TNF inhibitors in inflammatory bowel diseases. Pharmacol. Ther., 2016, 10.1016/j.pharmthera.2016.01.001.
49. Thurner, L., et al. Progranulin antibodies in autoimmune diseases. J. Autoimmun. 42 (2013), 29–38, 10.1016/j.jaut.2012.10.003.
50. Thurner, L., et al. Proinflammatory progranulin antibodies in inflammatory bowel diseases. Dig. Dis. Sci. 59 (2014), 1733–1742, 10.1007/s10620-014-3089-3.
51. Zhou, B., et al. Progranulin induces adipose insulin resistance and autophagic imbalance via TNFR1 in mice. J. Mol. Endocrinol. 55 (2015), 231–243, 10.1530/JME-15-0075.
52. Boehncke, W.H., Etiology and pathogenesis of psoriasis. Rheum. Dis. Clin. North Am. 41 (2015), 665–675, 10.1016/j.rdc.2015.07.013.
53. Huang, K., et al. Progranulin is preferentially expressed in patients with psoriasis vulgaris and protects mice from psoriasis-like skin inflammation. Immunology 145 (2015), 279–287, 10.1111/imm.12446.
54. Zhao, Y.P., Tian, Q.Y., Liu, C.J., Progranulin deficiency exaggerates, whereas progranulin-derived Atsttrin attenuates, severity of dermatitis in mice. FEBS Lett. 587 (2013), 1805–1810, 10.1016/j.febslet.2013.04.037.
55. Youn, B.S., et al. Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue. Diabetes 58 (2009), 627–636, 10.2337/db08-1147.
56. Qu, H., Deng, H., Hu, Z., Plasma progranulin concentrations are increased in patients with type 2 diabetes and obesity and correlated with insulin resistance. Mediators Inflamm., 2013, 2013, 360190, 10.1155/2013/360190.
57. Flehmig, G., et al. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PLoS ONE, 9, 2014, e99785, 10.1371/journal.pone.0099785.
58. Hossein-Nezhad, A., et al. Obesity, inflammation and resting energy expenditure: possible mechanism of progranulin in this pathway. Minerva Endocrinol. 37 (2012), 255–266.
59. Matsubara, T., et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 15 (2012), 38–50, 10.1016/j.cmet.2011.12.002.
60. Liu, J., et al. PGRN induces impaired insulin sensitivity and defective autophagy in hepatic insulin resistance. Mol. Endocrinol. 29 (2015), 528–541, 10.1210/me.2014-1266.
61. Li, H., et al. Administration of progranulin (PGRN) triggers ER stress and impairs insulin sensitivity via PERK-eIF2alpha-dependent manner. Cell Cycle 14 (2015), 1893–1907, 10.1080/15384101.2015.1041686.
62. Li, H., et al. Circulating PGRN is significantly associated with systemic insulin sensitivity and autophagic activity in metabolic syndrome. Endocrinology 155 (2014), 3493–3507, 10.1210/en.2014-1058.
63. Richter, J., et al. Serum levels of the adipokine progranulin depend on renal function. Diabetes Care 36 (2013), 410–414, 10.2337/dc12-0220.
64. Triebel, J., Comment on: Richter et al. Serum levels of the adipokine progranulin depend on renal function. Diabetes Care 2013;36:410-414. Diabetes Care, 36, 2013, e83, 10.2337/dc12-2275.
65. Xu, L., et al. Serum levels of progranulin are closely associated with microvascular complication in Type 2 diabetes. Dis. Markers, 2015, 2015, 357279, 10.1155/2015/357279.
66. Todoric, J., et al. Circulating progranulin levels in women with gestational diabetes mellitus and healthy controls during and after pregnancy. Eur. J. Endocrinol./Eur. Fed. Endocrine Soc. 167 (2012), 561–567, 10.1530/EJE-12-0060.
67. Tanaka, A., et al. Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis Res. Ther., 14, 2012, R244, 10.1186/ar4087.
68. Qiu, F., et al. Expression level of the growth factor progranulin is related with development of systemic lupus erythematosus. Diagn. Pathol., 8, 2013, 88, 10.1186/1746-1596-8-88.
69. Chen, X., Wen, Z., Xu, W., Xiong, S., Granulin exacerbates lupus nephritis via enhancing macrophage M2b polarization. PLoS ONE, 8, 2013, e65542, 10.1371/journal.pone.0065542.
70. Thurner, L., et al. The molecular basis for development of proinflammatory autoantibodies to progranulin. J. Autoimmun., 2015, 10.1016/j.jaut.2015.05.002.
71. Abraham, D.J., Krieg, T., Distler, J., Distler, O., Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48:Suppl 3 (2009), iii3–7, 10.1093/rheumatology/ken481.
72. Ichimura, Y., et al. Progranulin overproduction due to Fli-1 deficiency contributes to the resistance of dermal fibroblasts to tumor necrosis factor in systemic sclerosis. Arthrit. Rheumatol. 67 (2015), 3245–3255, 10.1002/art.39312.
73. Solis-Herruzo, J.A., Brenner, D.A., Chojkier, M., Tumor necrosis factor alpha inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J. Biol. Chem. 263 (1988), 5841–5845.
74. Kahari, V.M., Chen, Y.Q., Su, M.W., Ramirez, F., Uitto, J., Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1. Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels. J. Clin. Investig. 86 (1990), 1489–1495, 10.1172/JCI114866.
75. Yamane, K., Ihn, H., Asano, Y., Jinnin, M., Tamaki, K., Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J. Immunol. 171 (2003), 3855–3862.
76. Yamada, D., et al. Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis. Eur. J. Dermatol.: EJD 22 (2012), 351–357, 10.1684/ejd.2012.1702.
77. Siakavellas, S.I., Sfikakis, P.P., Bamias, G., The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. Semin. Arthritis Rheum. 45 (2015), 1–8, 10.1016/j.semarthrit.2015.02.007.
78. Fenoglio, C., et al. Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. Genes Immun. 11 (2010), 497–503, 10.1038/gene.2010.18.
79. Vercellino, M., et al. Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. Mult. Scler., 2015, 10.1177/1352458515610646.
80. Kamalainen, A., et al. GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients. J. Alzheimer's Disease: JAD 33 (2013), 23–27, 10.3233/JAD-2012-120946.
81. Chen, Y., et al. Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. J. Neurol. 262 (2015), 814–822, 10.1007/s00415-014-7630-2.
82. Nicholson, A.M., et al. Progranulin protein levels are differently regulated in plasma and CSF. Neurology 82 (2014), 1871–1878, 10.1212/WNL.0000000000000445.
83. Peri, Y., Agmon-Levin, N., Theodor, E., Shoenfeld, Y., Sjogren's syndrome, the old and the new. Best Pract. Res. Clin. Rheumatol. 26 (2012), 105–117, 10.1016/j.berh.2012.01.012.
84. Zhang, N., Yang, N., Chen, Q., Qiu, F., Li, X., Upregulated expression level of the growth factor, progranulin, is associated with the development of primary Sjogren's syndrome. Exp. Therap. Med. 8 (2014), 1643–1647, 10.3892/etm.2014.1981.
85. Thurner, L., et al. Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. Arthrit. Res. Ther., 15, 2013, R211, 10.1186/ar4406.
86. Zhao, Y.P., et al. Progranulin protects against osteoarthritis through interacting with TNF-alpha and beta-Catenin signalling. Ann. Rheum. Dis., 2014, 10.1136/annrheumdis-2014-205779.